gvtcx

NHS Framework for the NHS London Region, Branded Medicines - Tranche A

NHS England Published 12 Mar 2020 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£301,101,314
Statuscomplete
Category (CPV) 33600000
RegionNorth East, North West, Yorkshire and the Humber, East Midlands, West Midlands, East of England, London, South East, South West
Deadline15 Apr 2020
Contract start1 Sept 2020
Contract end31 Aug 2022
Procedureopen
SME suitableYes
OCIDocds-b5fd17-20ae12c6-3ba8-40bb-b423-51a2c2de6a67

Awards (28)

This procurement was awarded to 28 suppliers. Values shown are per-award; the notice total is £301,101,314.

SupplierValueDateStatus
AbbVie Ltd shared £191,062,951 16 Jun 2020 active
Accord UK Ltd shared £191,062,951 16 Jun 2020 active
Allergan Ltd shared £191,062,951 16 Jun 2020 active
Amgen Ltd shared £191,062,951 16 Jun 2020 active
Biogen Ltd. shared £191,062,951 16 Jun 2020 active
Bristol Myers Squibb Pharmaceutical Ltd shared £191,062,951 16 Jun 2020 active
Celltrion Healthcare United Kingdom Limited shared £191,062,951 16 Jun 2020 active
ELI LILLY & COMPANY LIMITED shared £191,062,951 16 Jun 2020 active
Ferring Pharmaceuticals Limited shared £191,062,951 16 Jun 2020 active
Gilead Sciences shared £191,062,951 16 Jun 2020 active
Ipsen Limited shared £191,062,951 16 Jun 2020 active
Janssen-Cilag Ltd shared £191,062,951 16 Jun 2020 active
Merck shared £191,062,951 16 Jun 2020 active
Merck Sharp & Dohme Ltd shared £191,062,951 16 Jun 2020 active
Merz Pharma UK Ltd shared £191,062,951 16 Jun 2020 active
Napp Pharmaceuticals Limited shared £191,062,951 16 Jun 2020 active
Novartis Pharmaceuticals UK Ltd shared £191,062,951 16 Jun 2020 active
Novo Nordisk Ltd shared £191,062,951 16 Jun 2020 active
Pfizer Ltd shared £191,062,951 16 Jun 2020 active
Pharmacosmos UK Ltd shared £191,062,951 16 Jun 2020 active
Roche Products Limited shared £191,062,951 16 Jun 2020 active
Sandoz Ltd shared £191,062,951 16 Jun 2020 active
Takeda UK Ltd shared £191,062,951 16 Jun 2020 active
Teva UK Limited shared £191,062,951 16 Jun 2020 active
Thornton and Ross Ltd shared £191,062,951 16 Jun 2020 active
UCB Pharma Ltd shared £191,062,951 16 Jun 2020 active
Vifor Pharma UK Limited shared £191,062,951 16 Jun 2020 active
ViiV Healthcare Limited shared £191,062,951 16 Jun 2020 active

description

NHS Framework for the NHS London Region, Branded Medicines - Tranche A, Annual Tranche - Cytokine Modulators and other products, and Dolutegravir / Lamivudine

Offer reference number: CM/PHR/16/5516

CM/PHR/16/5516/01 - London Tranche A - 1 September 2020 to 31 August 2022 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/16/5516/02 - London Annual Tranche - Cytokine Modulators and other products - 1 September 2020 to 31 August 2021 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

CM/PHR/16/5516/03 - NHS Framework agreement for the supply of Dolutegravir / Lamivudine - North of England - 1 September 2020 - 28 February 2021, South of England - 1 September 2020 - 31 August 2021, Midlands & East - 1 September 2020 - 28 February 2022, all with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
15 Sept 2020 Award (award) · 0e6f8f87-365c-4e84-90bf-6eb21339ba33-381349

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.